Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination With Gemcitabine Plus Cisplatin or Gemcitabine Alone in Subjects With Advanced Cancer

NCT02797977 is registered in ClinicalTrials.gov with Sierra Oncology LLC - a GSK company as lead sponsor.

NCT NCT02797977
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02797977 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination With Gemcitabine Plus Cisplatin or Gemcitabine Alone in Subjects With Advanced Cancer
Lead sponsor
Sierra Oncology LLC - a GSK company
Phase
Phase 1/2
Overall status
Completed
Start date
July 31, 2016
Completion date
April 8, 2020
Enrollment
153 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors